###### Strengths and limitations of this study

-   This is a comprehensive systematic review and meta-analysis that gives an overview of the effect of proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9-mAb) on inflammation.

-   An extensive systematic literature search identified all available randomised controlled trials that reported the changes of high-sensitivity C reactive protein using PCSK9-mAb.

-   Studies with moderate heterogeneity and lack of individual level data may limit the quality of evidence for this meta-analysis.

Introduction {#s1}
============

Cardiovascular disease is the greatest burden of global health, which is mainly characterised by atherosclerosis.[@R1] Atherosclerosis is a chronic and progressive inflammatory disease, including endothelial dysfunction, lipid accumulation in the arterial wall and leucocyte infiltration, which leads to luminal stenosis, plaque rupture and acute coronary syndrome (ACS).[@R2] Apart from well-established lipid theory, inflammation also plays an important role in the initiation and progression of atherosclerosis.[@R3] Recently, the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) reported that anti-inflammatory therapy by canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, significantly reduced the primary cardiovascular end points.[@R4] This study attracted attention to the inflammation intervention in cardiovascular medicine again.

C reactive protein (CRP), especially high-sensitivity CRP (hs-CRP), is the most intensively investigated inflammatory biomarker in cardiovascular field.[@R5] Increasing studies have confirmed that hs-CRP is a predictor for the progression of atherosclerotic disease and future major adverse cardiovascular events (MACE).[@R6] Moreover, previous studies also indicated that hs-CRP played a direct role in the progression of atherosclerosis.[@R8] Therefore, reduction of inflammatory markers such as hs-CRP may be a strategy for decreasing MACE.[@R10]

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is known to target low-density lipoprotein receptor for degradation resulting in elevated plasma low-density lipoprotein cholesterol (LDL-C) levels.[@R12] Recently, it has been reported that PCSK9 monoclonal antibody (PCSK9-mAb), as a novel lipid-lowering drug, can reduce LDL-C by a mean of 70% accompanied with reduction of MACE.[@R15] Although the relation of PCSK9 to LDL-C has been established, its role in inflammation has not been fully understood. Several experimental studies found that PCSK9 could promote the progression of atherosclerosis by enhancing inflammatory reaction.[@R16] On the other hand, PCSK9 deficiency could alleviate the inflammation reaction.[@R17] Hence, whether PCSK9-mAb can reduce inflammatory marker is clinically of great interest since it was used to treat cardiovascular diseases. A meta-analysis covering seven randomised controlled trials (RCTs) studies published 2 years ago suggested that PCSK9-mAbs had no effect on serum hs-CRP.[@R18] However, this meta-analysis may be limited by insufficient subgroup analyses, sample size and lack of newly published data.[@R19] Hence, we performed this meta-analysis including all RCTs published till May 2018 to further explore the efficacy of PCSK9-mAbs on circulating hs-CRP levels.

Methods {#s2}
=======

Literature search {#s2a}
-----------------

The present study is reported according to the guidelines of the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.[@R21] To identify all RCTs assessing the effect of PCSK9-mAbs on circulating hs-CRP levels, we comprehensively searched PubMed, MEDLINE, the Cochrane Library database and ClinicalTrials.gov up until May 2018. The search terms we used included the followings: (AMG145 or Evolocumab or REGN727 or SAR236553 or Alirocumab or RN316 or bococizumab or RG7652 or LY3015014 or PCSK9 antibody or anti-PCSK9) AND (randomized controlled trial OR randomized OR randomly). Meanwhile, manual search was performed for relevant studies including references lists, relevant review articles and commentaries (see online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}). No language restriction was used.
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Study selection {#s2b}
---------------

Original studies met the following criteria would be included: the design was phase 2 or phase 3 double-blind RCTs with longer than 8 weeks treatment duration; human participants were randomly assigned to PCSK9-mAbs group versus control group with or without other lipid-lowering therapy and outcomes included percentage changes of hs-CRP from baseline. Studies were excluded if they were duplicate publications, review articles, non-human studies, observational studies and lack of adequate information on outcomes or lacking control group. Two investigators (YC and SL) independently screened and selected the eligible studies. Disagreements were resolved by discussion with a third investigator.

Data extraction {#s2c}
---------------

A standardised extraction form was used to extract the following items by two investigators (YC and HL) independently: trial name/first author, year of publication, type of intervention, follow-up period, treatment duration, number of patients, participant characteristics, background lipid-lowering therapy, types and doses of PCSK9-mAbs, LDL-C and hs-CRP levels at baseline and changes. We included the final reported follow-up point if a trial contains several time points. If necessary, further information was required from correspondence author.

Quality assessment {#s2d}
------------------

We used Cochrane Collaboration's tool and Jadad score to assess the data and the methodological quality of included RCTs. For Cochrane Collaboration's tool, the following items were performed: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other sources of bias. The judgments were classified as 'low risk', 'high risk' and 'unclear risk' of bias. The 5-point Jadad score included the following items: basis of randomisation (0 to 2 points), double blinding (0 to 2 points) and withdrawals/dropouts (0 to 1 points). Studies with a score ≥3 points are considered to be high quality. Two investigators (YC and HL) independently assessed the quality of each study. Disagreements were resolved by discussion with a third investigator.

Data synthesis and statistical analysis {#s2e}
---------------------------------------

All analyses were conducted according to the intention-to-treat principles. For all efficacy outcomes, changes in hs-CRP concentrations were expressed as weighted mean difference (WMD) and 95% CI. All the data were standardised and expressed by mg/mL. SD could be calculated from CI, IQR or SE according to formulas in the Cochrane Handbook for Systematic Reviews of Interventions if not reported.

Heterogeneity was assessed by the Cochran Q test and the I^2^ statistic. We considered I^2^ \<25% as representing low heterogeneity and I^2^ \>75% as representing at high heterogeneity. Outcomes were calculated by fixed-effects models under no or low to moderate inconsistency (I^2^ \<50%); otherwise, the data were pooled based on random-effects models. Subgroups were applied to reduce the heterogeneity if I^2^ ≥50%, such as PCSK9-mAb types, treatment duration and participant characteristics. In order to explore the resource of heterogeneity, sensitivity analysis was conducted by omitting studies in turn to evaluate the consistency of the results. Meta-regression analyses were performed to evaluate the contribution of participant characteristics and reductions in LDL-C concentrations. Publication bias was assessed with a funnel plot and Egger's test.

All analyses were conducted with Review Manager V.5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration) and Stata V.14.0 (Stata Statistical Software, Stata Corp). P value \<0.05 was considered to be statistically significant.

Patient and public involvement statement {#s2f}
----------------------------------------

Participants and the public sector were not directly involved in the design and conduct of this study.

Results {#s3}
=======

Study selection and characteristics {#s3a}
-----------------------------------

The initial search identified 575 articles. After excluding duplicate publications and screening the titles and abstracts, 430 were excluded, and 145 studies were retrieved for full-text identification. We further excluded 135 studies, of which 58 were pooled or meta-analysis, 2 studies were not RCTs and 13 was phase 1 trials, 16 were open-label trails and 42 without adequate information. Finally, 10 studies were included in this meta-analysis.[@R20] [Figure 1](#F1){ref-type="fig"} shows flow diagram of selection process.

![Flow diagram of selection of studies.](bmjopen-2018-022348f01){#F1}

These 10 studies were published between 2012 and 2017 from different countries with low risk of bias, of which 5 were phase 2 studies and 5 were phase 3 studies ([table 1](#T1){ref-type="table"}). A total of 4198 participants were included, comprising 2728 individuals in the PCSK9-mAb group and 1470 in the control group. Alirocumab (SAR236553/REGN727) was used in 4 arms and 11 arms applied evolocumab (AMG 145). Five arms managed LY3015014 and two arms used RG7652. Four trials included patients with familial hypercholesterolaemia (FH), of which three were heterozygous FH and one was homozygous FH. Most of the treatment duration ranged from 12 to 24 weeks, and the longest treatment duration was 78 weeks. Apart from DESCARTES trial which coadministered with atorvastatin, another nine studies used PCSK9-mAb as monotherapy. Baseline characteristics including circulating hs-CRP levels were similar between PCSK9-mAbs and control groups within each study. The characteristics of these trials and participants are summarised in [table 1](#T1){ref-type="table"}. All these studies had a relatively high quality evaluated by the Jadad score and low risk of bias (online [supplementary table 1](#SP1){ref-type="supplementary-material"} and online [supplementary figures 1](#SP1){ref-type="supplementary-material"}, 3 scores=5, six scores=4).

###### 

Study characteristics of included randomised controlled trials.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                    Year   Phase   Inclusion criteria   Patients\    Arm     Mean age (years)                         Male\   Mean hs-CRP at baseline mg/L   hs-CRP reduction\   \% LDL-C reduction   Drugs/control        Treatment duration   Jadad Score
                                                               (n)                                                           %                                      (mg/L)                                                                             
  ------------------------ ------ ------- -------------------- ------------ ------- ---------------------------------------- ------- ------------------------------ ------------------- -------------------- -------------------- -------------------- -------------
  RUTHERFORD[@R22]         2012   II      HeFH                 167          \(1\)   47.6                                     54.5    1.09±1.37                      −0.06±0.94          42.7                 E:350 mg/PBO, Q4W    12W                  5

  \(2\)                    51.8   62.5    1.07±1.24            0.00±0.30    55.2    E:420 mg/PBO, Q4W                                                                                                                                                  

  Stein EA 2012[@R24]      2012   II      HeFH                 77           \(1\)   56.3                                     81.3    1·40±1.78                      −0.40±2.04          67.9                 A:150 mg/PBO, Q2W    12W                  5

  \(2\)                    51.3   60.0    0·60±0.82            −0.20±0.81   28.9    A:150 mg/PBO, Q4W                                                                                                                                                  

  \(3\)                    52.9   56.3    0·70±1.48            0.00±1.29    31.5    A:200 mg/PBO, Q4W                                                                                                                                                  

  \(4\)                    54.3   46.7    0.70±0.59            −0.10±0.84   42.5    A:300 mg/PBO, Q4W                                                                                                                                                  

  DESCARTES[@R25]          2014   II      HC                   894          \(1\)   50.7                                     47.3    2.00±3.70                      0.00±2.57           51.5                 E:420 mg/PBO, Q4W    52W                  5

  \(2\)                    57.2   42.9    1.00±1.48            0.00±1.48    54.7    E:420 mg+ATV 10 mg/PBO, Q4W                                                                                                                                        

  \(3\)                    57.8   52.4    1.00±1.48            0.00±1.48    46.7    E:420 mg+ATV 80 mg/PBO, Q4W                                                                                                                                        

  \(4\)                    54.2   55.6    1.00±1.48            0.00±1.48    46.8    E:420 mg+ATV 80 mg+Eze 10 mg /PBO, Q4W                                                                                                                             

  GAUSS-2[@R26]            2014   III     HC                   307          \(1\)   61.0                                     55.3    1.40±2.00                      0.30±2.67           56.1                 E:140 mg/Eze, Q2W    12W                  4

  \(2\)                    63.0   54.9    1.80±1.78            −0.30±1.78   52.6    E:420 mg/Eze, Q4W                                                                                                                                                  

  RUTHERFORD-2[@R23]       2014   III     HeFH                 329          \(1\)   52.6                                     40.0    0.92±1.03                      −0.05±0.39          61.3                 E:140 mg/PBO, Q2W    12W                  4

  \(2\)                    51.9   41.8    1.04±1.24            0.03±0.73    55.7    E:420 mg/PBO, Q4W                                                                                                                                                  

  TESLA Part B[@R27]       2014   III     HoFH                 49                   31.0                                     51.5    0.70±1.04                      −0.02±0.52          23.1                 E:140 mg/PBO, Q4W    12W                  4

  ODYSSEY COMBO II[@R28]   2015   III     HC                   720          \(1\)   61.7                                     75.2    3.58±7.78                      −0.39±6.95          50.6                 A: 75 mg/Eze, Q2W    24W                  4

  \(2\)                    61.7   75.2    3.58±7.78            −0.07±8.57   51.8    A: 75 mg/Eze, Q2W                        52W                                                                                                                       

  GLAGOV[@R29]             2016   III     HC                   968                  59.8                                     72.1    1.60±1.93                      −0.40±10.67         60.8                 E:420 mg/PBO, Q4W    78W                  4

  Kastelein 2016[@R20]     2016   II      HC                   519          \(1\)   57.2                                     51.7    1.03±1.41                      −0.20±2.07          14.9                 LY:20 mg/PBO, Q4W    16W                  4

  \(2\)                    57.1   52.3    1.34±1.11            1.60±2.00    40.5    LY:120 mg/PBO, Q4W                                                                                                                                                 

  \(3\)                    59.7   54.7    1.63±1.78            −0.30±2.00   50.5    LY:300 mg/PBO, Q4W                                                                                                                                                 

  \(4\)                    59.6   58.1    1.39±1.70            −0.30±2.07   14.9    LY:100 mg/PBO, Q8W                                                                                                                                                 

  \(5\)                    58.7   50.6    1.10±1.63            −0.70±2.07   37.1    LY:300 mg/PBO, Q8W                                                                                                                                                 

  EQUATOR[@R30]            2017   II      HC                   168          \(1\)   65.0                                     57.9    1.60±2.70                      0.34±1.93           23.3                 RG:400 mg/PBO, Q4W   24W                  4

  \(2\)                    64.0   51.0    2.00±5.90            −0.16±2.92   44.3    RG:800 mg/PBO, Q8W                                                                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data presented as mean ±SD.

A, alirocumab; ATV, atorvastatin; DESCARTES, Durable Effect of PCSK9 Antibody Compared with Placebo Study; E, evolocumab; EQUATOR: Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease; Eze, ezetimibe; GAUSS-2, Goal Achievement after Utilizing an Anti\[1\]PCSK9 Antibody in Statin Intolerant Subjects-2; GLAGOV, Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound; HC, hypercholesterolaemia; HeFH, heterozygous familial hypercholesterolaemia; HoFH, homozygous familial hypercholesterolaemia; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low -density lipoprotein cholesterol; LY: LY3015014; ODYSSEY COMBO II: Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins; RG, RG7652; RUTHERFORD, Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder; RUTHERFORD-2, Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder-2; PBO, placebo; Q2W, every 2 weeks; Q4W, every 4 weeks; W, weeks.

Efficacy outcomes of PCSK9-mAbs on hs-CRP {#s3b}
-----------------------------------------

A total of 4198 participants were included in the analysis of efficacy of PCSK9-mAbs on plasma hs-CRP concentrations before and after treatment. When data were pooled, PCSK9-mAbs showed a slight efficacy in reducing hs-CRP (WMD: −0.04 mg/L, 95% CI: −0.17 to 0.01), while no statistical difference was found compared with control treatment ([figure 2](#F2){ref-type="fig"}). There was a moderate heterogeneity between each study (I^2^=57.4%, p=0.0001), so the random-effect model was selected.

![Forest plots depicting the effect of PCSK9-mAbs on hs-CRP. PCSK9-mAb, proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody; hs-CRP, high-sensitivity C-reactive protein.](bmjopen-2018-022348f02){#F2}

To assess the potential discrepancy, we applied the subgroup analyses based on the characteristics of trials and participants ([figure 3](#F3){ref-type="fig"} and online [supplementary figures 2--5](#SP1){ref-type="supplementary-material"}). Although the efficacy of LY3015014 was a mild higher (−0.48 mg/L, 95% CI: −1.28 to 0.32), there was no difference between these four antibodies (alirocumab: 0.12 mg/L, 95% CI: −0.18 to 0.43; evolocumab: 0.00 mg/L, 95% CI: −0.07 to 0.07; RG7652: 0.35 mg/L, 95% CI: −0.26 to 0.96). When studies were classified by treatment duration, the hs-CRP reduction showed no difference in less than 12-week duration group (0.00 mg/L, 95% CI: −0.07 to 0.07) and above 12=week duration group (−0.11 mg/L, 95% CI: −0.45 to −0.23). There was no significant reduction in circulating hs-CRP with use of PCSK9 antibodies compared with control treatment when categorised to participant characteristics (FH: 0.00 mg/L, 95% CI: −0.07 to 0.07; non-FH: 0.07 mg/L, 95% CI: −0.12 to 0.26; mix: −0.48 mg/L, 95% CI: −1.28 to 0.32). The analysis stratified by treatment method also supported the results that no differential effect of PCSK9-mAb therapy on plasma hs-CRP concentrations was observed (monotherapy: 0.00 mg/L, 95% CI: −0.08 to 0.07 vs combination therapy: −0.08 mg/L, 95% CI: −0.37 to 0.21).

![Subgroup analyses of the effect of PCSK9-mAbs on hs-CRP. PCSK9-mAb, proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody; hs-CRP, high-sensitivity C-reactive protein; FH, familial hypercholesterolaemia; non-FH, non-familial hypercholesterolaemia.](bmjopen-2018-022348f03){#F3}

Sensitivity analysis and publication bias {#s3c}
-----------------------------------------

The sensitivity analysis for all outcomes was conducted by gradually removing each study. However, the results did not change meaningfully (online [supplementary figure 6](#SP1){ref-type="supplementary-material"}). Neither funnel plots (online [supplementary figure 7](#SP1){ref-type="supplementary-material"}) nor Egger's regression test (p=0.913) showed publication bias.

Meta-regression analyses {#s3d}
------------------------

We used meta-regression analyses to assess the relationship between changes in hs-CRP and baseline age, sex and average LDL-C changes (online [supplementary figure 8](#SP1){ref-type="supplementary-material"}). No statistically significant relationship between baseline age (p=0.673), male sex (p=0.645) and hs-CRP changes was observed. Likewise, LDL-C-lowering effects by PCSK9-mAb therapy had no impact on hs-CRP lowering (p=0.339, online [supplementary figure 8](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

The results of this updated, comprehensive meta-analysis, based on 10 RCTs encompassing 4198 participants, suggested that short-term PCSK9-mAb therapy had no impact on circulating hs-CRP concentrations. In the subgroup analyses, no difference was found between PCSK9-mAb types, participant characteristics and treatment duration or methods.

Atherosclerosis, a chronic progressive disorder, is characterised by lipid accumulation and chronic inflammation in the arterial wall.[@R2] Although previous data indicated a positive effects of anti-inflammatory drugs on atherosclerosis in animal studies, but no positive data were available in human studies.[@R31] Fortunately, recent evidence from CANTOS found that canakinumab significantly reduced hs-CRP levels and MACE after follow-up of 3.7 years which may support the inflammatory hypothesis of atherosclerosis.[@R4] Moreover, ongoing Cardiovascular Inflammation Reduction Trial was also designed to directly test the inflammatory hypothesis of atherosclerosis by evaluating the effect of methotrexate on adverse cardiovascular outcomes without substantive impact on lipids.[@R32] Hence, focusing on inflammation in the development of atherosclerosis may be an unsolved issue and great of interest clinically.

In fact, increasing studies indicated that hs-CRP could independently predict MACE.[@R6] Framingham study found that men and women in the highest quartile of CRP respectively had twice and three times the risk of stroke compared with those in the lowest ones after more than 10 years follow-up.[@R33] The Northern Manhattan Study reported that \>3 mg/L CRP was associated with a 1.7-fold increase in cardiovascular outcomes and a 1.55-fold increase in mortality.[@R34] Furthermore, it has been demonstrated that hs-CRP also plays a direct and vital role in the development of atherosclerosis. Zwaka *et al* [@R8] found that CRP enhanced the transformation from macrophages to foam cells by increasing the uptake of LDL-C. CRP was also reported to impair vasodilatation, inhibit the synthesis of nitric oxide synthase and facilitate the adhesion of monocyte.[@R35] Based on these evidence, reduction of hs-CRP may be associated with a decrease in MACE. Interestingly, the JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) study applied rosuvastatin on individuals with LDL-C levels below 130 mg/dL and hs-CRP levels ≥2 mg/L and suggested a significant reduction in all vascular events.[@R37] Although a fact that statins lower LDL-C and proportionately reduce MACE is widely accepted, the hs-CRP reduction by statin administration is also an attractive phenomenon, called as pleiotropic effect of statin. That is the reason why we chose hs-CRP as an inflammatory biomarker to identify whether PCSK9-mAb has an effect on inflammatory status.

Although the relationship between PCSK9 and LDL-C was well established, more and more evidence demonstrated its function beyond lipids. In 2010, microarray gene expression analysis suggested that PCSK9 affected cholesterol metabolism and inflammation.[@R38] Experimental studies indicated that PCSK9 could participate in vascular and systemic inflammation.[@R16] In transgenic mice expressing human PCSK9 gene, Tavori *et al* [@R39] observed that atherosclerosis lesion size and local Ly6C^hi^ monocytes, the precursors of proinflammatory M1 macrophages, significantly increased. Clinical studies further supported this hypothesis. Our previous study found that serum PCSK9 concentrations were independently associated with white blood cell count in patients with stable coronary artery disease, indicating PCSK9 might be involved in the inflammation process.[@R40] ATHEROREMO-IVUS (The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound) study reported a positive linearly association between PCSK9 levels and coronary plaque inflammation including amount of necrotic core tissue and plaque volume.[@R41] On the other hand, data also showed that PCSK9 inhibition could exert an anti-inflammatory effect. Tang *et al* [@R42] reported that PCSK9 small interfering RNA reduced the expression of proinflammatory genes through nuclear factor kappa B (NF-κB) pathway. In apoE−/− mice, PCSK9 silencing limited the development of atherosclerosis and decreased the number of macrophages via toll-like receptor 4-nuclear factor-kappa B (TLR4/NF-κB) signalling pathway.[@R43] Besides, AT04A anti-PCSK9 vaccine also got the same results that anti-PCSK9 therapy could reduce vascular inflammation.[@R44] Recently, Bernelot Moens *et al* [@R45] found that after 24 weeks of treatment with PCSK9-mAbs, the migratory capacity of monocytes and inflammatory responsiveness reduced significantly while anti-inflammatory cytokine levels increased in patients with FH. Therefore, we hypothesised that PCSK9-mAbs treatment could reduce hs-CRP in randomised clinical studies. Unfortunately, in our meta-analysis, the results showed that PCSK9-mAbs therapy had no effect on decreasing hs-CRP in both FH participants and non-FH individuals.

To explore the potential reasons why PCSK9-mAbs therapy was not benefit from inflammatory marker, named as the reduction of circulating hs-CRP levels, we further performed subgroup analyses. First, we did not observe an impact of PCSK9-mAbs types on hs-CRP, which may exclude the influence of PCSK9-mAbs itself on the inflammatory marker in our meta-analysis. Besides, the same results were also observed in combination of statins and PCSK9-mAbs group, suggesting that the effects of PCSK9-mAbs therapy on hs-CRP is not linked with treatment methods. It is notable that the participants in JUPITER trial had high levels of hs-CRP at baseline, while in PCSK9-mAb therapy, initial hs-CRP levels were at normal range in recruited individuals. Finally, we did not find a positive effects of PCSK9-mAbs therapeutic duration on hs-CRP in this updated analysis. Taken together, we may conclude that although PCSK9-mAbs had a powerful ability in lowering LDL-C, they had no impact on circulating hs-CRP concentration despite of PCSK9-mAb types, participant characteristics and treatment duration or methods.

Limitations {#s5}
===========

There were several limitations in our meta-analysis. First, our results were based on study data but not individual data as in most meta-analyses. Second, although our meta-analysis is an updated one, it is still limited by study numbers, sample size and therapy duration. Moreover, moderate degree of heterogeneity was observed in several comparisons. However, there was no publication bias, and the results were rather consistent among different subgroups. Sensitivity analysis suggested that the pooled WMD were robust. Finally, some studies included in this meta-analysis did not provide adequate information about blinding of participants and personnel.

Conclusions {#s6}
===========

In conclusion, the current updated evidence suggested that PCSK9-mAb, a novel powerful lipid-lowering drug, had no significant impact on circulating hs-CRP concentrations, whose effect did not influenced by PCSK9-mAb types, participant characteristics and treatment duration or methods. Long-term observation may be needed.
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